vimarsana.com

Page 15 - மாசசூசெட்ஸ் அடிப்படையிலானது மாடர்னா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Moderna vaccine shows 94 1% efficacy in a Phase 3 clinical trial

Moderna vaccine shows 94.1% efficacy in a Phase 3 clinical trial There were no safety issues found and the side effects have been mild, though more research is needed on its effect on transmission. , Associate Editor The investigational vaccine known as mRNA-1273 was 94.1% effective in preventing symptomatic COVID-19, according to preliminary results from a Phase 3 clinical trial reported in The New England Journal of Medicine. The vaccine also demonstrated efficacy in preventing severe COVID-19, and investigators identified no safety concerns or evidence of vaccine-associated enhanced respiratory disease (VAERD). The vaccine was codeveloped by Massachusetts-based Moderna and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Moderna and NIAID previously shared initial results from the COVE trial. On Dec. 18, 2020, the FDA issued an emergency use authorization allowing Moderna to make the vaccine available

How tech is reinventing healthcare

Israel G Vargas “It’s time to get rid of the scars,” says Mark Slack, a gynaecologist and co-founder of robotic surgery startup CMR Surgical. Cambridge-based CMR Surgical was founded in 2014 – Slack remembers how, when the company started, surgeons wanted a robot that was suitable for all surgical disciplines: equivalent in cost to a straight-stick surgery, adaptable to any theatre, modular and quick to set up and take down. “There was nothing like it,” he says. “So what did we do? We had to build our own robot.” The result is the Versius, a surgical robot designed to help surgeons perform keyhole surgery. Today, the company employs around 500 people and, after raising more than $100 million (£75.2 million) in June 2018, it’s now valued at more than $1 billion (£759 million), making it one of the rare unicorns in medtech.

COVID-19 pandemic turns 50 doctors, scientists and healthcare entrepreneurs into billionaires

The pandemic has helped turn dozens of healthcare leaders into billionaires According to Forbes, 50 doctors, scientists and healthcare entrepreneurs earned billionaire status this year with the majority being from China  Of the 50 new billionaires, 28 hail from China, where virus first emerged in 2019 One notable new billionaires is Uğur Şahin, the physician who co-founded BioNTech, which helped develop the Pfizer vaccine Another notable new billionaire is Stéphane Bancel, the CEO of Moderna The COVID-19 pandemic has helped 50 healthcare leaders become billionaires, with 28 hailing from China, where the virus first emerged in December 2019, according to Forbes.  The first case of the coronavirus was reported in Wuhan last year before quickly spreading across the world and killing more than 1.7 million people. In the US alone, there are more than 19 million confirmed infections and at least 332,723 Americans have died. 

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.